ProCE Banner Activity

Experts Discuss Key Questions in Treating Advanced GI Cancers

Clinical Thought

In this commentary, 3 experts answer questions from a live meeting on recent findings that may affect clinical management of patients with colorectal, gastric/gastroesophageal, and pancreatic cancers.

Released: March 21, 2023

Share

Faculty

Christopher H. Lieu

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

John Marshall

John Marshall, MD

Medstar Hematology/Oncology
Director, Ruesch Center for Cure of GI Cancers
Lombardi Comprehensive Cancer Center Georgetown University
Washington, DC

Manish Shah

Manish Shah, MD

Chief, Solid Tumor Services
Bartlett Family Professor of Gastrointestinal Oncology
Director, Gastrointestinal Oncology Program
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Astellas

AstraZeneca

Elevation Oncology

Merck Sharp & Dohme Corp.

Merus NV

Seagen Inc.

Faculty Disclosure

Primary Author

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Christopher H. Lieu, MD: researcher: Merck.

John Marshall, MD

Medstar Hematology/Oncology
Director, Ruesch Center for Cure of GI Cancers
Lombardi Comprehensive Cancer Center Georgetown University
Washington, DC

John L. Marshall, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Caris, Indivumed, Merck, Pfizer, Seagen, Taiho.

Manish Shah, MD

Chief, Solid Tumor Services
Bartlett Family Professor of Gastrointestinal Oncology
Director, Gastrointestinal Oncology Program
Weill Cornell Medical College
New York, New York

Manish Shah, MD: researcher: Bristol-Myers Squibb, Merck.